CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤患者 CAR-T 细胞治疗后的细胞因子释放综合征：系统综述
英文原题：Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review.
查看英文原题
Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
本综述获得的结果表明，接受 CAR-T 细胞治疗的弥漫大 B 细胞淋巴瘤患者中细胞因子释放综合征发生率较高，然而这些事件可控，支持该疗法在这类患者中安全的结论。
研究思路结论见上方概要
背景
CAR-T（CAR-T）细胞疗法是一项创新技术，在临床试验中已显示出令人鼓舞的结果。该治疗基于对患者自身T细胞进行改造，使其表达人工表面受体，从而特异性识别并攻击肿瘤细胞。
目的
综合现有关于接受CAR-T 细胞治疗的弥漫性大B细胞淋巴瘤患者中细胞因子释放综合征发生率和治疗策略的证据。
方法
这是一项系统性文献综述。检索在PubMed、Scopus和Web of Science数据库中进行。本综述遵循系统综述和荟萃分析首选报告项目（PRISMA）指南。该系统综述方案已在国际前瞻性系统综述注册库（PROSPERO）中注册，注册号为CRD42022359258。
结果
共纳入19项研究，涉及1193例接受CAR-T 细胞治疗的患者。在这些患者中，804例（67%）出现了不同程度的细胞因子释放综合征。3级和4级细胞因子释放综合征的发生率分别为10%和3%。该综合征管理中最常用的方案包括tocilizumab和/或糖皮质激素。
展开英文摘要原文
OBJECTIVE
To synthesize available evidence on the incidence and management strategies of cytokine release syndrome in patients with diffuse large B-cell lymphoma who received CAR-T cell therapy.
METHODS
This is a systematic literature review. The search was conducted in the PubMed, Scopus, and Web of science databases. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The systematic review protocol is registered in the International Prospective Register of Systematic Reviews (PROSPERO) database under number CRD42022359258.
RESULTS
Nineteen studies were included with a total of 1193 patients who received CAR-T cell therapy. Of these patients, 804 (67%) developed some degree of cytokine release syndrome. The frequencies of Grade 3 and 4 cytokine release syndrome were 10% and 3%, respectively. The regimen most used in the management of the syndrome included tocilizumab and/or glucocorticoids.
CONCLUSION
The results obtained in this review demonstrate high rates of cytokine release syndrome in patients with diffuse large B-cell lymphoma treated with CAR-T cell therapy, however these events are manageable, supporting the conclusion that this therapy is safe in these patients.
论文信息
- 作者
- Rodrigues Dos Santos A、Zanini D、Andolfatto D
- 单位
- Associação Hospitalar Lenoir Vargas Ferreira, Chapecó, SC, Brazil. Electronic address: andressarodriguesfarma@hotmail.com.Brazil
- 文献类型
- 综述
- 期刊
- Hematology, transfusion and cell therapy2024 Dec
- 原文标识
- PubMed 39089933 · DOI 10.1016/j.htct.2024.05.005
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →